



- 07 February 2022** Louis M. Staudt, National Cancer Institute, Bethesda, U.S.A.
Rational development of targeted therapies for genetic subtypes of aggressive lymphoma
- 14 February 2022** Delfim Duarte, i3S, Porto, Portugal
Microenvironment and iron in acute myeloid leukemia
- 21 February 2022** Dan Landau, Weill Cornell Medical College/ New York Genome Center, New York, U.S.A.
Charting clonal hematopoietic differentiation topologies with single cell multi-omics
- 28 February 2022** Charles Mullighan, St. Jude Comprehensive Cancer Center, Memphis, U.S.A.
Lineage ambiguous leukemia
- 07 March 2022** Stuart H. Orkin, Harvard Medical School/ HHMI, Boston, U.S.A.
Reactivation of fetal hemoglobin for therapy of hemoglobin disorders
- 14 March 2022** Peter van Galen, Brigham and Women's Hospital/ Harvard Medical School/ Broad Institute, Boston, U.S.A.
Tracing leukemia evolution and immune cell interactions using single cell multi-omics
- 21 March 2022** Heiko Bruns, University Hospital Erlangen, Erlangen, Germany
Function and significance of tumor-associated macrophages in lymphoma
- 28 March 2022** Peter Campbell, Wellcome Sanger Institute, Hinxton, U.K.
Somatic mutations in normal tissues
- 04 April 2022** Lisa Russell, Newcastle University, Newcastle upon Tyne, U.K.
Super-enhancer activation of proto-oncogenes in acute lymphoblastic leukaemia: from discovery to treatment

Every Monday
16:00-17:00 hrs /
04:00-05:00 PM CET



- 11 April 2022** Cécile Denis, INSERM, Le Kremlin-Bicetre, France
New developments in von Willebrand factor research
- 25 April 2022** Wilbur Lam, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, U.S.A.
Development and clinical translation of engineered microsystems in hematology
- 02 May 2022** John W. Weisel, University of Pennsylvania, Philadelphia, U.S.A.
Mechanisms of blood clot contraction and its significance for hemostasis and thrombosis
- 09 May 2022** Mihai Netea, Radboud University Medical Center, Nijmegen, The Netherlands
Trained immunity: a memory for innate host defense
- 16 May 2022** Jolanta Grembecka, University of Michigan, Ann Arbor, U.S.A.
Targeted inhibition of epigenetic modifiers in leukemia
- 23 May 2022** Jens Lohr, Dana-Farber Cancer Institute, Boston, U.S.A.
Promiscuous lineage identity and clinical implications in patients with multiple myeloma
- 30 May 2022** Siddhartha Jaiswal, Stanford University School of Medicine, Stanford, U.S.A.
Clonal hematopoiesis in human aging and disease
- 20 June 2022** Roni Shouval, Memorial Sloan Kettering Cancer Center, New York, U.S.A.
Hallmarks of response and toxicity to CAR T-cell therapy
- 27 June 2022** Ivo Touw, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Molecular pathogenesis of congenital neutropenia